The Future of the Biodefense Industry

Regulation, Funding Opportunities & Company Profiles

Publication Date	September 2009
Publisher	Business Insights
Product Type	Report
Pages	183
ISBN Number	not applicable
Product Code	RBI00337

Buy this product or for assistance call +44 20 7060 7474

PDF £2,305.00$3834 | €2580

PRINT £2,365.00$3934 | €2647

FAX Order above formats by FAX

Summary

The major contemporary bioterrorist event which has opened up programs of research and development (R&D) in pharmaceutical countermeasures and treatments was the anthrax mail attacks which occurred only weeks after the 9/11 atrocities, in October 2001. The mailings killed five people and exposed hundreds more ??

Content

Executive summary
- Setting the scene
- Regulatory environment
- Major pathogens for BW
- Biodefense funding
- Company profiles
- Future perspectives
Chapter 1 Setting the scene
- Summary
- Introduction
- The use of biological agents in warfare and terrorism
- Warfare
- Offensive BW programs
- Bioterrorism: Extent and nature of the threat
- Creation
- Bulk manufacture
- Weaponization
- Delivery
- Future threats
- Pre-2001 bioterrorism
- 2001 - September 11 and the anthrax attacks
Chapter 2 Regulatory environment
- Summary
- Introduction
- US bodies
- FDA
- Center for Biologics Evaluation and Research (CBER)
- Center for Drug Evaluation and Research (CDER)
- Office of Counterterrorism and Emerging Threats
- National Institutes of Health (NIH)
- The National Institute of Allergy and Infectious Diseases (NIAID)
- Biomedical Advanced Research and Development Authority
- (BARDA)
- Public Health Emergency Medical Countermeasures Enterprise
- (PHEMCE)
- Project Bioshield
- Centers for Disease Control and Prevention (CDC)
- US Army Medical Materiel Development Activity (USAMMDA)
- European bodies
- European Commission
- European Council Health Security Committee
- European Centre for Disease Prevention and Control (ECDC)
- The European Medicines Agency (EMEA)
- Economic Commission for Europe
- Joint Commission/Pharmaceutical Industry Task Force
- 2009-2011 Indicative Program for the Instrument for Stability
- International Agencies
- World Health Organisation (WHO)
- United Nations
- Global Health Security Initiative (GHSI)
Chapter 3 Major pathogens for BW
- Summary
- Introduction
- Anthrax
- Developmental therapeutics and vaccines
- Plague
- Developmental therapeutics and vaccines
- Tularemia
- Developmental therapeutics and vaccines
- Smallpox
- Developmental therapeutics and vaccines
- Viral Hemorrhagic Fevers - Ebola, Marburg, Crimean-Congo, Hantavirus, Lassa
- Developmental therapeutics and vaccines
- Botulism
- Developmental therapeutics and vaccines
- Ricin
- Developmental therapeutics and vaccines
- Staphylococcal enterotoxins
- Developmental therapeutics and vaccines
- Brucella group
- Developmental therapeutics and vaccines
- Glanders
- Developmental therapeutics and vaccines
- Melioidosis (Whitmore's disease)
- Developmental therapeutics and vaccines
- Q fever
- Developmental therapeutics and vaccines
- Conclusion
Chapter 4 Biodefense funding
- Summary
- US funding
- Department of Health and Human Services (HHS)
- Biomedical Research and Development Authority (BARDA)
- Department of Homeland Security (DHS)
- Other departments
- Grants available for biodefense R&D in the US
- NIH Challenge grants in health & science research
- NIH Cooperative Research & Development Agreement (CRADA)
- Small business awards
- NIH small business biodefense program awards
- Project BioShield awards
- Regional Centers of Excellence for Biodefense and Emerging
- Infectious Diseases (RCE)
- Defense Threat Reduction Agency (DTRA)
- US Army Medical Research Institute of Infectious Diseases (USAMRIID)
- Technology transfer
- Defense Advanced Research Projects Agency (DARPA)
- European funding
- United Kingdom
- France
- Germany
- EU biodefense programs
- European Defense Agency (EDA)
- EDA's Joint R&D Investment Program
- Bio-Edep
- Bioterrorism Research Resilience Reaction (BIO3R)
- Biodefense industry
- New and Emerging Science and Technology (NEST)
- Health Protection Agency (HPA)
- Defense Science and Technology Laboratory (Dstl)
- Japan
Chapter 5 Company profiles
- Summary
- Introduction
- US
- Achaogen
- Contracts
- Advanced Life Sciences
- Contracts
- Alnylam Pharmaceuticals
- Contracts
- Cleveland BioLabs
- Contracts
- Dynavax Technologies Inc
- Contracts
- Dynport Vaccine Company Llc (DVC)
- Contracts
- Elusys Therapeutics
- Contracts
- Emergent BioSolutions
- Contracts
- Ichor Medical Systems
- Contracts
- Nanotherapeutics
- Contracts
- Peregrine Pharmaceuticals, Inc
- Contracts
- PharmAthene
- Contracts
- SIGA Technologies
- Contracts
- VaxGen
- Contracts
- XOMA
- Contracts
- Canada
- Affinium Pharmaceuticals
- Contracts
- Cangene
- Contracts
- ID Biomedical Corporation
- Contracts
- UK
- Acambis
- Contracts
- Cambridge Biostability (CBL)
- Contracts
- MNLpharma
- Contracts
- Denmark
- Bavarian Nordic
- Contracts
- Australia
- Vaxine Pty
- Contracts
- India
- Panacea Biotec Ltd
- Contracts
- China
- Sinovac Biotech Ltd
- Israel
- Medison Pharma
- Conclusion
- Biodefense products: the risks
Chapter 6 Future perspectives
- Summary
- Introduction
- Assessing future threats
- GM technology
- Synthetic biology
- US funding ??